Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide
Molecules · 2023
DOI: 10.3390/molecules28227548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Yangmei Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Peptides, Cyclic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute for Health, Office of the Vice President for Research at the University of South Carolina.
Abstract (Originalsprache)
Peptide-based opioid ligands are important candidates for the development of novel, safer, and more effective analgesics to treat pain. To develop peptide-based safer analgesics, we synthesized a mixture-based cyclic pentapeptide library containing a total of 24,624 pentapeptides and screened the mixture-based library samples using a 55 °C warm water tail-withdrawal assay. Using this phenotypic screening approach, we deconvoluted the mixture-based samples to identify a novel cyclic peptide Tyr-[D-Lys-Dap(Ant)-Thr-Gly] (CycloAnt), which produced dose- and time-dependent antinociception with an ED50 (and 95% confidence interval) of 0.70 (0.52–0.97) mg/kg i.p. mediated by the mu-opioid receptor (MOR). Additionally, higher doses (≥3 mg/kg, i.p.) of CycloAnt antagonized delta-opioid receptors (DOR) for at least 3 h. Pharmacological characterization of CycloAnt showed the cyclic peptide did not reduce breathing rate in mice at doses up to 15 times the analgesic ED50 value, and produced dramatically less hyperlocomotion than the MOR agonist, morphine. While chronic administration of CycloAnt resulted in antinociceptive tolerance, it was without opioid-induced hyperalgesia and with significantly reduced signs of naloxone-precipitated withdrawal, which suggested reduced physical dependence compared to morphine. Collectively, the results suggest this dual MOR/DOR multifunctional ligand is an excellent lead for the development of peptide-based safer analgesics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA.
- Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
- Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL 34987, USA.
ORCID-Profile: Yangmei Li, Michelle Ganno-Sherwood, Jay P McLaughlin
Förderung
- NIGMS NIH HHS
- National Institute for Health
- Office of the Vice President for Research at the University of South Carolina
Zitieren
APA
Li, Y., Eans, S. O., Ganno-Sherwood, M., Eliasof, A., Houghten, R. A., & McLaughlin, J. P. (2023). Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide. Molecules. https://doi.org/10.3390/molecules28227548
Vancouver
Li Y, Eans SO, Ganno-Sherwood M, Eliasof A, Houghten RA, McLaughlin JP. Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide. Molecules. 2023. doi:10.3390/molecules28227548
BibTeX
@article{Li2023,
author = {Li, Yangmei and Eans, Shainnel O and Ganno-Sherwood, Michelle and Eliasof, Abbe and Houghten, Richard A and McLaughlin, Jay P},
title = {Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28227548}
}
EUVIMED